

A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France

NCT07343089

Status RECRUITING
Sponsor University Hospital, Strasbourg, France
Enrollment 100 participants

Key Eligibility Criteria

Inclusion (2)

- Minor or adult subject
- Having presented disseminated borreliosis confirmed by molecular biology (*Borrelia burgdorferi* s.l. or *Borrelia miyamotoi*) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.

Exclusion (1)

- Refusal to participate in the study

Locations (1 total)

Laboratoire de Bactériologie - CHU de Strasbourg - France, Strasbourg, France